We previously showed TS-overexpressing colon cancer cells remained relatively sensitive to F10 [19], a polymeric fluoropyrimidine that showed promising activity in multiple pre-clinical cancer models including AML [22], ALL [54], GBM [55], and prostate cancer [18]. Here, TYMS is linked to prostate carcinoma.